Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology leader pioneering CRISPR/Cas9 gene editing therapies. This page serves as the definitive source for official company announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated press releases detailing NTLA's progress in treating genetic disorders like hereditary angioedema and ATTR amyloidosis. Content spans therapeutic pipeline developments, intellectual property advancements, and collaborative research initiatives with industry partners.
All materials are organized to facilitate quick scanning of critical updates while maintaining technical accuracy. Regular updates ensure stakeholders stay informed about NTLA's work in precision gene editing without promotional bias.
Bookmark this page for direct access to Intellia's latest financial reports, scientific publications, and conference participation details. Check back frequently for real-time updates on CRISPR-based therapeutic innovations.
Intellia Therapeutics (NASDAQ:NTLA) reported longer-term Phase 1 data for one-time IV nexiguran ziclumeran (nex-z) in ATTR amyloidosis with cardiomyopathy as of an Aug 23, 2025 data cut. Across 36 patients, a single dose produced rapid, deep and durable serum TTR reduction through three years (mean 87% reduction at 36 months; mean TTR 22.9 µg/mL).
At 24 months, markers showed stability or improvement (NT-proBNP 70%, hs-Troponin T 85%, 6MWT 69%, NYHA 81% stable/improved) and a post-hoc matched analysis showed lower all-cause mortality (3.9 vs 12.7 per 100 patient-years; HR 0.27; p=0.009). Safety findings were consistent with prior data (IRRs, transaminase elevations; liver enzymes ≤ Grade 2).
Intellia Therapeutics (NASDAQ: NTLA) presented pooled Phase 1/2 data for a one-time 50 mg IV dose of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Nov 8, 2025.
Key results: mean plasma kallikrein reduction of 89% at month 24; 31 of 32 patients (97%) were attack-free and long-term prophylaxis (LTP)-free at data cutoff (Aug 29, 2025); 24 of 32 (75%) were attack-free and LTP-free ≥7 months (up to 32 months). Of 11 Phase 2 patients dosed 50 mg, 10 were attack-free and LTP-free.
Safety: well-tolerated with up to three years follow-up, one resolved pulmonary embolism in a patient with risk factors, one transient Grade 2 AST elevation, and no new long-term risks identified. Phase 3 HAELO topline readout expected by mid-2026.
Intellia Therapeutics (NASDAQ:NTLA) reported Q3 2025 results and clinical updates on November 6, 2025. The company said the FDA placed a clinical hold on the MAGNITUDE and MAGNITUDE-2 Phase 3 trials of nex-z after rare Grade 4 liver transaminase elevations; more than 650 patients are enrolled in MAGNITUDE and 47 patients in MAGNITUDE-2. Intellia completed enrollment in the Phase 3 HAELO trial of lonvo-z and expects topline HAELO data by mid-2026, with a potential U.S. launch in 1H 2027. Cash, cash equivalents and marketable securities were $669.9M at September 30, 2025, and are expected to fund operations into mid-2027. Third-quarter net loss was $101.3M.
Intellia Therapeutics (NASDAQ:NTLA) announced a temporary pause of patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nexiguran ziclumeran (nex-z) for ATTR-CM and ATTR-PN after an October 24, 2025 safety event.
The event involved a patient dosed on September 30, 2025 who developed Grade 4 liver transaminase elevations and increased total bilirubin, met protocol pausing criteria, was hospitalized and is receiving care. The company said it is consulting experts and engaging regulators. As of October 27, 2025, >650 ATTR-CM patients are enrolled in MAGNITUDE, 47 patients in MAGNITUDE-2, and an estimated >450 patients have been dosed with nex-z. A conference call and webcast were scheduled for 8:30 a.m. ET the same day.
Intellia Therapeutics (NASDAQ:NTLA) announced on October 1, 2025 inducement equity awards to six new employees under its 2024 Inducement Plan. The grants total 65,200 RSUs of common stock, vesting one‑third on Oct 1, 2026, 2027 and 2028, subject to continued service. The awards were granted outside Intellia’s stockholder‑approved plans and were approved by the compensation committee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan was adopted by the board in June 2024. No cash amounts, price terms, or pro forma share dilution metrics were included in the release.
Intellia Therapeutics (NASDAQ:NTLA) has reported promising long-term Phase 1 data for nexiguran ziclumeran (nex-z) in treating hereditary ATTR amyloidosis with polyneuropathy. The single-dose treatment demonstrated sustained TTR reductions of at least 90% through three years, with significant clinical improvements.
Key findings include: 92% mean serum TTR reduction at 24 months in patients receiving ≥0.3 mg/kg doses (n=33), and 90% reduction at 36 months (n=12). Among 18 patients evaluated at 24 months, 72% showed clinically meaningful improvements in mNIS+7 scores. The treatment was generally well-tolerated, with only mild to moderate infusion-related reactions reported.
The company's Phase 3 MAGNITUDE-2 trial is progressing rapidly, with enrollment completion expected in H1 2026 and a potential BLA submission targeted for 2028.
Intellia Therapeutics (NASDAQ:NTLA) will present extended follow-up data from its Phase 1 trial of Nexiguran Ziclumeran (nex-z), a CRISPR-based gene editing therapy for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).
The presentation will take place at the 5th International ATTR Amyloidosis Meeting on September 25, 2025 in Baveno, Italy. Dr. Julian Gillmore from the National Amyloidosis Centre will present efficacy and safety data including up to three years of patient follow-up and disease-relevant measures.
Intellia Therapeutics (NASDAQ:NTLA) has achieved a significant milestone by completing enrollment in its global Phase 3 HAELO study for lonvoguran ziclumeran (lonvo-z), a CRISPR-based therapy for hereditary angioedema (HAE). The study enrolled over 60 patients within nine months, with nearly half from the U.S.
The company expects to report topline data in H1 2026, followed by a BLA submission in H2 2026, targeting a U.S. launch in H1 2027. The HAELO study is a randomized, double-blind, placebo-controlled trial evaluating lonvo-z's efficacy in patients aged 16 and older with Type I or II HAE. Additional Phase 1/2 study data will be presented in Q4 2025.
Intellia Therapeutics (NASDAQ:NTLA) reported strong Q2 2025 results and significant progress in its clinical programs. The company ended Q2 with $630.5 million in cash, expecting to fund operations into H1 2027. Key highlights include accelerated enrollment in the Phase 3 MAGNITUDE trial for ATTR-CM, which will expand to approximately 1,200 patients, and the Phase 3 HAELO study for HAE completing randomization ahead of schedule.
The company presented compelling three-year follow-up data for lonvo-z in HAE, showing a 98% reduction in monthly attack rates. For nex-z in ATTR amyloidosis, Phase 1 data demonstrated strong TTR reduction in both wild-type and variant ATTR-CM patients. The company strengthened its commercial readiness with key leadership appointments and remains on track for BLA submission for lonvo-z in H2 2026.
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has granted inducement awards to five new employees under its 2024 Inducement Plan. The awards consist of 18,200 restricted stock units (RSUs) of Intellia's common stock.
The RSUs will vest in three equal installments on August 1 of 2026, 2027, and 2028, subject to continued employment. These awards were granted outside the company's stockholder-approved equity incentive plans and were approved by Intellia's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
FAQ
What is the current stock price of Intellia Therape (NTLA)?
What is the market cap of Intellia Therape (NTLA)?
